Change in croup score. · children with croup
4 findings from 1 review
Show 1 more finding
Change in croup score. · children with croup
4 findings from 1 review
Show 1 more finding
Return visits or (re)admissions or both · children with croup
Any glucocorticoid showed no clear difference in return visits or (re)admissions or both compared with epinephrine (low certainty).
1 finding from 1 review
Adverse events · children with croup
1 finding from 1 review
Return visits or (re)admissions or both · children with croup
Any glucocorticoid may leads to lower return visits or (re)admissions or both compared with placebo (low certainty).
1 finding from 1 review
Adverse events · children with croup
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · people with psychosis
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Global state: No clinically significant response (as defined by the original studies) · people with psychosis
1 finding from 1 review
General functioning: improved to an important degree · people with psychosis
2 findings from 1 review
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with psychosis
1 finding from 1 review
Quality of life: improved to an important degree · people with psychosis
3 findings from 1 review
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
no estimate extracted
0 studies · 0 participants
GRADE not reported
Mental state · people with psychosis
2 findings from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · people with psychosis
2 findings from 1 review
Global state: general ‐no clinically significant improvement ‐ data only for mifepristone < 30% improvement on BPRS · people with psychosis
It is very uncertain whether any antiglucocorticoid changes global state: general ‐no clinically significant improvement ‐ data… compared with placebo (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · people with psychosis
1 finding from 1 review
Adverse effects: 1. General ‐ overall number of events · people with psychosis
Any antiglucocorticoid probably leads to higher adverse effects: 1. General ‐ overall number of events compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events: 2. Specific ‐ extrapyramidal symptoms ‐ average endpoint scores ‐ data only for DHEA SHRS total · people with psychosis
1 finding from 1 review
Mean depression scores ‐ HAMD · people with psychosis
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Global state: 1. General ‐ no clinically significant improvement ‐ short term < 30% improvement on BPRS · people with psychosis
Any antiglucocorticoid may leads to lower global state: 1. General ‐ no clinically significant improvement ‐… compared with placebo (low certainty).
1 finding from 1 review
Global state: 2. Specific: positive ‐ no clinically significant improvement ‐ short term (< 50% improvement on BPRS PSS) · people with psychosis
Any antiglucocorticoid may leads to lower global state: 2. Specific: positive ‐ no clinically significant… compared with placebo (low certainty).
1 finding from 1 review